Skip to main content

Advertisement

SpringerLink
Log in

Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification

  • Research Article
  • Published:
Tumor Biology

Abstract

The incidence of lung adenocarcinoma has been increased significantly year by year. In this histologic type, complete surgical resection is commonly chosen as treatment method at the initial stages. However, the postoperative survival rate remains unsatisfactory even within the stage I. The purpose of this study is to investigate the factors related with prognosis in stage I lung adenocarcinoma after surgical resection. In this manuscript, a retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The results indicated that a total of 531 patients were included. Overall 5-year survival was 81.2 %. Age, sex, pathologic stage, T category, tumor size, differentiation, necrosis, visceral pleural invasion (VPI), lymphatic vessel or vascular invasion, and serum carcinoembryonic antigen (CEA) were significantly associated with 5-year overall survival of the patients with Kaplan-Meier analysis. Moreover, on multivariate analyses, seven variables were shown to be independent prognostic factors, including differentiation (hazard ratios (HR), 1.357), VPI (HR, 0.551), lymphatic vessel or vascular invasion (HR, 0.533), necrosis (HR, 1.671), age (HR, 1.519), pathological stage (HR, 4.477), and CEA (HR, 2.099). In conclusion, the most important prognostic factor is pathologic stage. Other adverse prognostic factors include differentiation, VPI, lymphatic vessel or vascular invasion, necrosis, age, and CEA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, et al. The single nucleotide polymorphism g.1548A > G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biol. 2012;33(5):1429–36.

    Article  CAS  Google Scholar 

  2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.

    Article  CAS  PubMed  Google Scholar 

  3. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3(4):457–66.

    Article  PubMed  Google Scholar 

  4. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9.

    Article  CAS  PubMed  Google Scholar 

  5. Goldstraw P. New staging system: how does it affect our practice? J Clin Oncol. 2013;31(8):984–91.

    Article  CAS  PubMed  Google Scholar 

  6. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Geneva: UICC International Union Against Cancer; 2009. 136–146.

    Google Scholar 

  7. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73–7.

    PubMed  Google Scholar 

  8. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74(5):1640–6.

    Article  PubMed  Google Scholar 

  10. Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3):364–72.

    Article  PubMed  Google Scholar 

  11. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653–64.

    Article  CAS  PubMed  Google Scholar 

  12. Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2013. [Epub ahead of print]

  13. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  14. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(8):593–602.

    Article  PubMed  Google Scholar 

  15. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131(5):1014–20.

    Article  PubMed  Google Scholar 

  16. Chang YL, Lin MW, Shih JY, Wu CT, Lee YC. The significance of visceral pleural surface invasion in 32 1 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol. 2012;19(9):3057–64.

    Article  PubMed  Google Scholar 

  17. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.

    Article  PubMed  Google Scholar 

  18. Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, et al. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings. Eur J Cardiothorac Surg. 2004;25(5):877–83.

    Article  PubMed  Google Scholar 

  19. Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, et al. Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumor Biol. 2013;34(4):2233–9.

    Article  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, 241 West Huaihai Road, Shanghai, 200030, People’s Republic of China

    Xiaohong Fan, Xueyan Zhang, Huimin Wang & Bo Jin

Authors
  1. Xiaohong Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xueyan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huimin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohong Fan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fan, X., Zhang, X., Wang, H. et al. Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification. Tumor Biol. 35, 5905–5910 (2014). https://doi.org/10.1007/s13277-014-1781-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1781-8

Keywords

Search

Navigation